Do you guys remember when a year ago or so, in a GILD conf call, the CEO or CSO said when asked on M&As opportunities, that they had lost the train on CAR-T? I expected a deal in oncology but not in CAR-T. I bet they think they can charge big for these drugs, even not for everybody
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.